NHS trust adopts Clinithink’s AI-driven clinical data processing platform

Worcestershire-adopts-Clinithink-software-service.jpg
(Image: Getty/gopixa) (Getty Images/iStockphoto)

NHS GDE Trust Worcestershire Health and Care collaborates with Clinithink to better manage its clinical data through the latter’s ‘natural language processing’ platform.

Clinithink, a company developing artificial intelligence (AI)-enabled data management software, announced its partnership with Worcestershire Health and Care, a Global Digital Exemplar (GDE) trust of the UK’s National Health Service (NHS).

Under the partnership, the NHS trust, which provides children’s and mental health services in the city of Worcestershire, has started using Clix Enrich, a clinical natural language processing (CNLP) platform, developed by Clinithink.

The software platform uses AI technology to ‘read’ and interpret clinical documents, automating the review of clinical notes and mining unstructured clinical narrative. According to Clinithink, the platform is able to process up to two million documents an hour.

The software also includes reporting tools able to provide predictive population analytics to support the disease diagnostic process, according to the company.

The use of Clix Enrich by Worcestershire is expected to reduce clinical risk and increase the organization’s productivity to support its clinical research programs.

According to David Brown, I director at Worcestershire, the platform “is delivering real gold dust” to the health organization, which needs to record approximately 26,000 patient contacts every week.

The main advantages of Clix Enrich, according to Brown, include the use of SNOMED coding to query the unstructured clinical narrative that makes up the majority of the patients’ clinical record.

“This approach allows us to search and display crucial clinical content in a format that the team can use as part of their clinical practice and decision making process,” Brown added.

Clinithink launched Clix Enrich in 2016 and has since then collaborated on it with healthcare providers in the UK and the US, as well as biopharmaceutical companies and contract research organisations.